Lotus Eye Hospital & Institute (BOM:532998) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


BOM:532998 Lotus Eye Hospital & Institute Ltd BOM:532998
66 GF Score
Price ₹126.50
GF Value ₹91.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Lotus Eye Hospital & Institute Research & Development?

Lotus Eye Hospital & Institute BOM:532998 +5.90% 66 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:532998 with a GF Score™ of 66/100 and a GF Value™ of ₹91.88 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lotus Eye Hospital & Institute's Research & Development for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Lotus Eye Hospital & Institute  (BOM:532998) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lotus Eye Hospital & Institute Research & Development Related Terms

Lotus Eye Hospital & Institute Research & Development Historical Data

* Premium members only.

The historical data trend for Lotus Eye Hospital & Institute's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Eye Hospital & Institute Research & Development Chart

Lotus Eye Hospital & Institute Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lotus Eye Hospital & Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:532998
66GF Score
Lotus Eye Hospital & Institute Ltd BOM:532998
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lotus Eye Hospital & Institute Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Lotus Eye Hospital & Institute (BOM:532998) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Lotus Eye Hospital & Institute and its competitors.
Is Lotus Eye Hospital & Institute's Research & Development too high?
Lotus Eye Hospital & Institute's current Research & Development is ₹0.0 Mil. Overall, Lotus Eye Hospital & Institute has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lotus Eye Hospital & Institute's Research & Development compare to HCA and THC?
Lotus Eye Hospital & Institute's Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lotus Eye Hospital & Institute and its competitors. Lotus Eye Hospital & Institute's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Eye Hospital & Institute stock overvalued right now?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute (BOM:532998) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.88, compared to a current price of ₹126.50 — trading 37.7% above its estimated fair value. The current Research & Development is ₹0.0 Mil. Lotus Eye Hospital & Institute's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lotus Eye Hospital & Institute (BOM:532998), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Eye Hospital & Institute (BOM:532998) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Eye Hospital & Institute stock appears to be overvalued. The current stock price of ₹126.50 is trading 37.7% above its estimated GF Value™ of ₹91.88. GuruFocus considers Lotus Eye Hospital & Institute to be Significantly Overvalued.

Key valuation signals for BOM:532998:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹91.88 vs. price of ₹126.50 (37.7% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BOM:532998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lotus Eye Hospital & Institute Business Description

Other Exchanges LOTUSEYE:India
Address SF No. 770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore, TN, IND, 641 014
Lotus Eye Hospital & Institute Ltd is an India-based eye care hospital. It is engaged in providing treatment and care for eye diseases and disorders. It offers treatment services for eye conditions like refractive error, retina and uvea, cornea, glaucoma, pediatric, orbit and oculoplasty, neuro-ophthalmology, and binocular vision. In addition, the company also operates an eye bank for functioning eye donation activities. The company mainly operates in India and generates revenue by providing medical services, pharmacy sales, contact lenses, and optical, of which the majority of the revenue is derived from providing segmmedical services.
66GF Score

Get the complete analysis for BOM:532998

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹126.50
Price
₹91.88
GF Value